In vivo studies in K-RAS-driven human LUAD xenografts and PDXs exhibiting KEAP1 mutations show a reduction in tumor growth after treatment with glutaminase inhibitor CB-839 [110]. This evidence concerns the gene KEAP1 and neoplasm.